The direct binding of DUXAP8 to histone methyltransferase (enhancer of zeste homolog2, EZH2) and histone demethylase (Lysine Demethylase 1A, LSD1) has been firmed, indicating that DUXAP8 exerts its tumor-promotive activity at least partly through epigenetic modification of the target genes (46, 47). This evidence concerns the gene EZH2 and neoplasm.